[Comparative study of relative biovailability of several spironolactone formulations in a steady-state test (author's transl)].
By the US Food and Drug Administration spironolactone is regarded as a drug with problems related to bioavailability. A steady-state study was performed comparing the 50- and 100-mg formulations of two manufacturers with each other. Applying a fluorimetric method to both canrenone and canrenoate--the major biologically active metabolites of spironolactone--the two brands were compared in 11 volunteers for the 50 mg, and in 10 volunteers for the 100 mg dosage form.
D000328:Adult; D001682:Biological Availability; D002191:Canrenoic Acid / Q000378:metabolism; D002192:Canrenone / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D013148:Spironolactone / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D013997:Time Factors
D013148:Spironolactone; D002192:Canrenone; D002191:Canrenoic Acid
Vergleichende Untersuchung der relativen Bioverfügbarkeit mehrerer Spironolacton-Zubereitungen im Steady-state-Versuch.